Werewolf Therapeutics operates as an oncology biotherapeutics company.
Werewolf Therapeutics has raised $50.0M in total funding. The most recent round was Post-IPO Secondary. The last funding was announced in May 2022.
Werewolf Therapeutics's investors include RA Capital Management, Adage Capital Management, Longwood Fund, Taiho Ventures, Deerfield.
Werewolf Therapeutics is headquartered in Cambridge, United States.
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Werewolf Therapeutics is at the Post-IPO Secondary stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Werewolf Therapeutics — Funding & Investors." VCBacked, May 10, 2022, https://www.vcbacked.co/company/werewolf-therapeutics. Accessed November 13, 2026.
VCBacked. (2022). Werewolf Therapeutics — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/werewolf-therapeutics
{{cite web |title=Werewolf Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/werewolf-therapeutics |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Werewolf Therapeutics? Request a listing update